Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC37953 Lateritin Featured
Lateritin is An Acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor and a platelet aggregation inhibitor isolated from the mycelial cake of Gibberella lateritium; bassiatin is the (3S,6R) isomer.
More description
DC12603 TED-347 Featured
TED-347 (TED347) is an irreversible inhibitor of TEAD4-Yap1 protein-protein interaction (EC50=5.9 uM in FP asssays) via covalent modification of conserved cysteine (Cys367, Ki=1.3 uM), inhibits its binding to Yap1, blocked its transcriptional activity.
More description
DC12456 BTT-266 Featured
BTT-266 (BTT266) is a voltage-gated CaV2.2 calcium channel inhibitor that disrupts the CaVα·CaVβ3 protein-protein interaction, directly binds to CaVβ3 with Kd of 3.6 uM.
More description
DC23691 ML090 Featured
ML090 (ML-090, CCG-44699, Fluoflavin, NSC 179821) is a potent, selecitve inhibitor of NADPH oxidase 1 (NOX1) with IC50 of 90 nM, displays no significant activities against NOX2, 3 and 4 (IC50>10 uM)..
More description
DC42631 rTRD01 Featured
Novel TDP-43 ligand, binding to TDP-43's RRM1 and RRM2 domains, partially disrupting TDP-43's interaction with the hexanucleotide RNA repeat of the disease-linked c9orf72 gene, improving larval turning, an assay measuring neuromuscular coordination and st
More description
DC71588 SRI-37330 hydrochloride Featured
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research.
More description
DC11286 WJ460 Featured
WJ460 is one of the lead compounds exerting anti-metastatic activity in the nanomolar range in breast cancer cells.
More description
DC72750 GNE-9822 Featured
GNE-9822 is a potent, orally active and selective ITK inhibitor with a Ki value of 0.7 nM. GNE-9822 has good ADME properties. GNE-9822 can be used in research of asthma.
More description
DC70798 SRX3177 Featured
SRX3177 is a potent, triple BRD4/PI3K/CDK4/6 inhibitor with nanomolar potency against PI3Kα (IC50=79 nM), BRD4 bromodomains (BD1 and BD2) (IC50=33 nM and 89 nM, respectively), and CDK4/6 (IC50=2.5/3.3 nM).SRX3177 is capable of targeting BRD4, PI3K and CDK4/6 simultaneously, induces apoptosis and cell cycle arrest and has in vitro efficacy in mantle cell lymphoma, hepatocellular carcinoma and neuroblastoma models.SRX3177 has antitumor efficacy in in vivo xenograft models and is less toxic than the combination of agents that inhibit individual targets.
More description
DC47388 PROTAC SHP2 degrader-1 Featured
PROTAC SHP2 degrader-1 is a potent and effective SHP2 degrader. PROTAC SHP2 degrader-1 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins and is also neddylation- and proteasome-dependent.
More description
DC71874 MIF098 Featured
MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.
More description
DC43804 VAS3947 Featured
Selective inhibitor of NADPH oxidase activity in low micromolar concentrations, interfering neither with ROS detection nor with XOD or eNOS activities
More description
DC44929 Cyclotriazadisulfonamide Featured
Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.
More description
DC21437 OAT-2068 Featured
OAT-2068 is a potent, selective, orally bioavailable inhibitor of mouse chitotriosidase (mCHIT1) with IC50 of 29 nM, 143-fold selectivity over mAMCase.
More description
DC34054 PHPS1 Featured
PHPS1 is an inhibitor of the protein tyrosine phosphatase Shp2. PHPS1 also efficiently inhibits activation of Erk1/2 by the leukemia-associated Shp2 mutant, Shp2-E76K, and blocks the anchorage-independent growth of a variety of human tumor cell lines.
More description
DC12414 ZLc002 Featured
ZLc002 (ZLc-002) is a putative small-molecule inhibitor of nNOS interaction with NOS1AP, disrupts neuronal nitric oxide synthase-NOS1AP interaction in intact cells.
More description
DC42752 HaloPROTAC3 Featured
HaloPROTAC3 is a degrader of HaloTag fusion proteins.
More description
DC46419 11R-VIVIT TFA Featured
11R-VIVIT TFA is a cell-permeable nuclear factor of activated T cells (NFAT) inhibitor. 11R-VIVIT TFA can be used for the research of podocyte and diabetic nephropathy.
More description
DC71577 Haloperidol lactate Featured
Haloperidol lactate is a potent antipsychotic agent. Haloperidol lactate can be used in acute and chronic schizophrenia and gilles de la tourette's syndrome. Haloperidol lactate has the potential for the research of psychotic disorders.
More description
DC70873 USP10 inhibitor Wu-5 Featured
USP10 inhibitor Wu-5 (Wu-5) is a novel small molecule USP10 inhibitor inducing the degradation of FLT3-mutated protein, directly interacts and inactivates USP10, the deubiquitinase for FLT3-ITD in vitro (IC50=8.3 uM) and in FLT3-ITD-positive AML cells.Wu-5 selectively inhibited the viability of FLT3 inhibitor-sensitive (MV4-11, Molm13) and -resistant (MV4-11R) FLT3-ITD-positive AML cells with IC50 of 3.794, 5.056, and 8.386 uM, respectively.Wu-5 (1-10 μM) dose-dependently induced apoptosis of MV4-11, Molm13, and MV4-11R cells through the proteasome-mediated degradation of FLT3-ITD.Combined treatment of Wu-5 and crenolanib produced synergistic cell death in FLT3-ITD-positive cells via the reduction of both FLT3 and AMPKα proteins.
More description
DC42568 SIRT6 activator 12q Featured
Novel SIRT6 activator, significantly inhibiting the proliferation and migration of pancreatic ductal adenocarcinoma (PDAC) cells in vitro and markedly suppressing the tumor growth in a PDAC tumor xenograft model
More description
DC42627 FFN246 Featured
Novel fluorescent substrate for both the serotonin transporter and the vesicular monoamine transporter 2 (VMAT2)
More description
DC22669 ONO-1301 Featured
A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.
More description
DC40078 MAP4343 Featured
MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.
More description
DC24178 Moxifloxacin Featured
A fourth-generation synthetic fluoroquinolone, broad-spectrum antibacterial agent that is active against both Gram-positive and Gram-negative bacteria.
More description
DC11554 FT-671 Featured
FT-671 is a novel potent, specific, non-covalent USP7 inhibitor with Kd of 65 nM (USP7 catalytic domain).
More description
DC20653 ALE-0540 Featured
ALE-0540 is a nerve growth factor (NGF) antagonist that inhibits the binding of NGF to TrkA or both p75 and TrkA with IC50 of 5.88 and 3.72 uM, respectively.
More description
DC43566 (E)-Flupentixol dihydrochloride Featured
(E)-Flupentixol is a non-neuroleptic isomer of (Z)-flupenthixol.
More description
DC33159 PF-06279794 Featured
PF-06279794, also known as PF-794, is a potent, selective and ATP-competitive TNIK inhibitor.
More description
DC20225 Dapansutrile Featured
Dapansutrile is a β-sulfonyl nitrile inhibitor of the NLRP3 inflammasome that inhibits the release of IL-1β and decreases caspase-1 levels in LPS-stimulated J774A.1 murine macrophages, human monocyte derived macrophages (HMDMs), and primary human blood ne
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X